SCHEMBL7708350

SCHEMBL7708350

CC1=C(N)Nc2cc(CN(Cc3ccc([N+](=O)[O-])cc3)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1D1 P20393 1/20 0.40
MMP1 P03956 4/20 0.35
MMP2 P08253 4/20 0.35
MMP9 P14780 4/20 0.35
MMP8 P22894 4/20 0.35
MMP13 P45452 4/20 0.35
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
SLC2A1 P11166 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 2/20 0.33
NR3C2 P08235 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711186 0.92 NR3C2 (0.41) SLC2A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7711366 0.89 HDAC1 (0.37) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7708189 0.89 HDAC3 (0.37) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7704910 0.88 HDAC1 (0.45) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7704965 0.87 HDAC3 (0.36) NR1D1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7708353 0.87 GRM2 (0.37) NR1D1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7713435 0.86 HDAC1 (0.34) HDAC3HDAC1HDAC2NCOR2
SCHEMBL7710748 0.86 CA2 (0.35) HDAC3HDAC1HDAC2NCOR2
SCHEMBL7711328 0.86 HDAC3 (0.35) HDAC3HDAC1HDAC2NCOR2MAPT
SCHEMBL7704946 0.86 ALDH1A1 (0.38) NR1D1SLC2A1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed